| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18740 R79693 |
Moore (Levetiracetam) (Epilepsy) (Controls exposed to LTG), 2025 | Early childhood developmental concerns (any developmental concerns on any domain at the 27–30 month assessment offered to all children) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
1.10 [0.77;1.58] C excluded (control group) |
71/260 90/354 | 161 | 260 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18738 R79687 |
Moore (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2025 | Early childhood developmental concerns (any developmental concerns on any domain at the 27–30 month assessment offered to all children) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes Matched | 1.20 [0.89;1.63] | 71/260 645/2,600 | 716 | 260 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12772 R48172 |
Bjørk (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2022 | Neurodevelopmental Disorder (ND): any diagnoses of autism spectrum disorder (F84.0, F84.1, F84.5) or intellectual disability (F70, F71, F72, F73) plus F84.3, F84.4, F84.8, F84.9, F79 - Median follow up levetiracetam 3.6 (1.8-6.5) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
0.61 [0.32;1.18] C excluded (control group) |
10/1,017 81/5,073 | 91 | 1,017 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12773 R48176 |
Bjørk (Levetiracetam) (Controls unexposed NOS), 2022 | Neurodevelopmental Disorder (ND): any diagnoses of autism spectrum disorder (F84.0, F84.1, F84.5) or intellectual disability (F70, F71, F72, F73) plus F84.3, F84.4, F84.8, F84.9, F79 - Median follow up levetiracetam 3.6 (1.8-6.5) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: Yes |
1.58 [0.85;2.94] excluded (control group) |
10/1,017 68,295/4,463,879 | 68,305 | 1,017 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12774 R48180 |
Bjørk (Levetiracetam) (Controls unexposed, sick), 2022 | Neurodevelopmental Disorder (ND): any diagnoses of autism spectrum disorder (F84.0, F84.1, F84.5) or intellectual disability (F70, F71, F72, F73) plus F84.3, F84.4, F84.8, F84.9, F79 - Median follow up levetiracetam 3.6 (1.8-6.5) years old | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 1.06 [0.56;2.02] | 10/1,004 443/21,634 | 453 | 1,004 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7807 R23117 |
Coste (Levetiracetam) (Controls unexposed, NOS), 2020 | Diagnosis Disorders of psychological development (F80–F89) (mean age of 3.6 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 1.20 [0.50;2.90] | 5/621 10,010/1,710,441 | 10,015 | 621 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S301 R24952 |
Arkilo (Levetiracetam), 2015 | Abnormal development (At 2 years of age, assessed by developmental specialists) | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick | Adjustment: No | 0.41 [0.02;9.32] C | 0/11 2/24 | 2 | 11 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 4 studies | 1.17 [0.90;1.51] | 11,186 | 1,896 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Levetiracetam) (Epilepsy) (Controls unexposed, sick; 2: Levetiracetam) (Controls unexposed, sick; 3: Levetiracetam) (Controls unexposed, NOS; 4: Levetiracetam;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 12772, 12773, 18740